Insulin long-acting (HM 12460A) - Hanmi Pharmaceutical

Drug Profile

Insulin long-acting (HM 12460A) - Hanmi Pharmaceutical

Alternative Names: HM 12460A; HM 12460B; LAPS-Insulin - Hanmi Pharmaceutical; LAPSInsulin; Ultra-Long Acting Insulin - Hanmi Pharmaceutical

Latest Information Update: 17 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 08 Feb 2018 Hanmi Pharmaceuticals completes a phase I trial for Type-1 and Type-2 diabetes mellitus (In volunteers) in USA (IV) (NCT03330314)
  • 22 Nov 2017 Phase I development is ongoing USA for Type-2 diabetes mellitus
  • 10 Nov 2017 HM 12460A is still in phase I trials for Type 2 diabetes in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top